Published in Cancer Weekly, June 24th, 2008
"We compared the effects of the two compounds on human prostate cancer LNCaP and PC3...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.